| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | BIRB 0796 | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |